Literature DB >> 8599993

Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study.

D Ribatti1, A Vacca, B Nico, M Fanelli, L Roncali, F Dammacco.   

Abstract

Samples of lymph nodes from 88 patients with B-cell non-Hodgkin's lymphoma (B-NHL) grouped by the Working Formulation (WF) and from 15 patients with benign lymphadenopathies were investigated immunohistochemically and ultrastructurally for changes in angiogenesis and stromal distribution of two subendothelial basement membrane (BM) components, namely laminin and type IV collagen. The microvessel number was usually low in lymphadenopathies, and increased significantly in low-grade B-NHL. Intermediate-grade tumors displayed a further significant increase that was mainly due to their diffuse subtypes rather than to the follicular subtype. High-grade B-NHL showed the highest counts. By contrast with the lymphadenopathies studied, the stroma of B-NHL reacted intensely with both BM components, whose linear co-expression was significantly associated with low-grade and follicular intermediate-grade B-NHL, while expression of laminin alone in a granular pattern was detected in diffuse intermediate-grade and high-grade tumors. Ultrastructural analysis revealed immature vessels more frequently in diffuse intermediate-grade, and in high-grade B-NHL. These in situ data suggest that angiogenesis occurring in B-NHL increases along their progression path, and emphasize the importance of angiogenesis as an epigenetic phenomenon of B-NHL progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599993     DOI: 10.1111/j.1600-0609.1996.tb00293.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  36 in total

Review 1.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

2.  The role of the vascular phase in solid tumor growth: a historical review.

Authors:  D Ribatti; A Vacca; F Dammacco
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

3.  Mechanism and Function of Angiogenin in Hematopoietic Malignancy.

Authors:  Kevin A Goncalves; Guo-Fu Hu
Journal:  Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao       Date:  2015-12-23

4.  What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?

Authors:  R F Nicosia
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

5.  Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide.

Authors:  T Michigami; M Nomizu; Y Yamada; C Dunstan; P J Williams; G R Munday; T Yoneda
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

Review 6.  The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.

Authors:  Allison J Li; Laura M Calvi
Journal:  Exp Hematol       Date:  2017-08-18       Impact factor: 3.084

7.  Kaposi's sarcoma-associated herpesvirus glycoproteins B and K8.1 regulate virion egress and synthesis of vascular endothelial growth factor and viral interleukin-6 in BCBL-1 cells.

Authors:  R Subramanian; I Sehgal; O D'Auvergne; K G Kousoulas
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

8.  Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.

Authors:  Michael Medinger; Natalie Fischer; Alexandar Tzankov
Journal:  J Oncol       Date:  2010-05-24       Impact factor: 4.375

Review 9.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

Review 10.  Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.

Authors:  J Ruan; K Hajjar; S Rafii; J P Leonard
Journal:  Ann Oncol       Date:  2008-12-16       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.